Eli Lilly is set to release a once-daily pill to rival Ozempic this year. People are losing 15 to 20 pounds on it, but there's a catch.

"Lilly's pill "outperformed" Novo's "on every key endpoint we measured, including A1C and weight loss," lead trial investigator Dr. Julio Rosenstock, an endocrinologist and diabetes and metabolism expert, said in a release."

"The trial, which lasted for one year and included 1,698 patients with diabetes on three continents, is the latest big win for Lilly, which has been racing ahead of its competitors in developing new and improved formulations of GLP-1 drugs."

"If all goes well with the US Food and Drug Administration in the coming months, orforglipron could be available to US consumers by this spring, with prices rivaling a "fancy gym membership," according to one analyst."

Eli Lilly announced that its GLP-1 pill orforglipron surpassed Novo Nordisk's oral semaglutide in a year-long clinical trial involving 1,698 diabetes patients across three continents. Lilly's pill demonstrated superior performance on all measured endpoints, including A1C levels and weight loss, with patients achieving 15 to 20 pounds of weight loss and heart health improvements. This represents another competitive victory for Lilly, whose injectable tirzepatide previously outperformed injectable semaglutide. Orforglipron could reach US consumers by mid-2026 at approximately $300 monthly. Novo Nordisk's existing pill Rybelsus requires specific administration protocols, while Lilly's formulation offers greater convenience and efficacy advantages.

Read at Business Insider